Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -- Received U.S. Food and Drug